Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD2389 in Adult Participants With Steatotic Liver Disease and Advanced Fibrosis (BRAVO)

NCT07610837 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07610837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07610837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD2389 in Adult Participants With Steatotic Liver Disease and Advanced Fibrosis (BRAVO)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
May 7, 2026
Completion date
July 7, 2027
Enrollment
104 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

hepatic cirrhosis, liver fibrosis